Spironolactone and colitis: Increased mortality in rodents and in humans [PDF]
, 2012 Background: Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context
Akbar K. Waljee +40 more
core +1 more source
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]
, 2019 When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia +2 more
core +1 more source
Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study [PDF]
, 2017 Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factors ...
Boswood, A +4 more
core +3 more sources
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. [PDF]
PLoS ONE, 2012 OBJECTIVE: Aldosterone, one of the main peptides in renin angiotensin aldosterone system (RAAS), has been suggested to mediate liver fibrosis and portal hypertension.
Wei Luo +10 more
doaj +1 more source
Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study [PDF]
, 2011 1. Abstract 1.1. Aims: Sleep disordered breathing (SDB) may contribute to disease progression in patients with chronic heart failure (CHF). The objective of this observational study was to evaluate whether SDB is a risk factor for mortality in CHF ...
Krenn, Marion
core +1 more source
A combined clinical and biomarker approach to predict diuretic response in acute heart failure [PDF]
, 2015 Background: Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood.
Bloomfield, Daniel M. +16 more
core +4 more sources
Anti-inflammatory Effect of Spironolactone on Human Peripheral Blood Mononuclear Cells
Journal of Pharmacological Sciences, 2006 .: We evaluated the effect of alacepril, CV-11974, and spironolactone on the production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) in cultured human peripheral blood mononuclear cells stimulated with angiotensin
Miura Ryuzea +10 more
doaj +1 more source
Contemporary Clinical Trials Communications, 2020 Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model.
Alkomiet Hasan +25 more
doaj +1 more source
Association is not causation: treatment effects cannot be estimated from observational data in heart failure [PDF]
, 2018 Aims: Treatment ‘effects’ are often inferred from non-randomized and observational studies. These studies have inherent biases and limitations, which may make therapeutic inferences based on their results unreliable.
Campbell, Ross T. +4 more
core +1 more source
Acta Dermato-VenereologicaAcne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne.
Brigitte Dréno +16 more
doaj +1 more source